MAR | Interim Report January – June 2019


”With CADScor®System we have a fantastic opportunity to revolutionize the way the healthcare system handles patients with suspected coronary artery disease, CAD. In our daily work at Acarix, we see that the need for precise tools to make quick and appropriate decisions continues to grow, and Acarix has an important role to play in fulfilling that need.” Extract from CEO Per Persson’s message to the Interim Report.

Acarix_Q2_2019 (english)

Acarix_Q2_2019 sv

About Acarix
Acarix was establish in 2009 and is listed on Nasdaq First North Growth Market. Acarix's CADScor@System uses an advanced sensor placed on the skin above the heart to listen to the sounds of cardiac contraction movement and turbulent flow. It has been designed to be an all-in-on system in the sense that the heart signal will be recorded, processed, and displayed as a patient specific score, the CAD-score, on the device screen.